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The Editorial on the Research Topic
Tumor-Derived Extracellular Vesicles: Protocols, Models, and Clinical Evidence
The current frontiers in Oncology are at the nanoscale (1). Within this nanoworld, new instruments 
and their related protocols enable the discovery or the improved characterization of bio-objects 
including extracellular vesicles (EVs). EVs, secreted by cells into the extracellular environment, 
include exosomes, microvesicles, and apoptotic bodies. Thus, EVs range from approximately 
40 nm to a few millimeters in size (2). Deriving from the endosomal compartment, exosomes are 
cell-secreted nanovesicles within the 70–150 nm diameter range that have recently aroused a great 
interest in the scientific and clinical community for their roles in intercellular communication in 
almost all physiological and pathological processes (2).
The growing interest for exosomes in biology stems from the fact that these vesicles: (i) are 
ubiquitous (e.g., from plants to eukaryotic cells); (ii) contain a variety of molecules including signal 
peptides, mRNAs, microRNAs (miRNAs), proteins, and lipids; (iii) are involved in local and systemic 
cell communication (exosomes can bind to cells through receptor–ligand interactions, can also pass 
through the blood–brain barrier and the placenta); (iv) all living cells can release exosomes including 
tumor cells; and (v) can be detected in body fluids (e.g., blood and urine).
In Oncology, the many characteristics and roles of circulating tumor-derived exosomes are being 
elucidated (3–7). This research topic aims at providing recent findings and reviews to contribute to 
the maturation of this emerging field with high clinical potential.
Exosomes carry biologically active molecules including non-coding RNAs (ncRNAs) that are usu-
ally divided into two major groups according to their length: small ncRNAs (below 200 nt) defined 
as miRNAs and long ncRNAs (lncRNAs; above 200 nt). miRNAs mostly act on RNA by silencing 
or posttranscriptionally regulating gene expression, whereas lncRNAs participate in imprinting and 
gene dosage regulation, using diverse molecular mechanisms. In their review, Lopatina et al. mainly 
focus on the role of EV-transferred RNAs carried by tumor-derived and mesenchymal stem cells 
(MSC)-derived EVs and how they can alter tumor microenvironment. They gather evidences sug-
gesting that ncRNAs can not only modulate gene expression locally but also systemically. They also 
show that depending on their biological properties and content, EVs are involved in cancer initiation, 
progression, and premetastatic niche formation. It is becoming evident that EVs may transfer not 
only functional ncRNA but also DNA, thus modifying gene expression in recipient cells and further 
extending EVs communication modalities. In line with the article of Al-Nedawi, they pinpoint the 
dual role of exosomes and stress out the probable importance of the environment.
2Seigneuric and Garrido Tumor-Derived Extracellular Vesicles
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 230
The group of Takahashi et al. describes methods for the isola-
tion of EVs from the cell culture supernatant and from human 
serum and the extraction of extracellular RNA by digital PCR 
(dPCR). Quantitative real-time polymerase chain reaction 
(qPCR) is a widely adopted technique since its invention in the 
mid 80s (8, 9). dPCR, developed in the late 90s, extends these 
applications while providing an increased sensitivity (10). Each 
sample is partitioned into thousands (~104 to ~106) nanoliter 
to picoliter-sized droplets moving through microfluidics chips 
where a PCR either occurs (1) or not (0). dPCR also provides 
interesting improvements including increased precision and 
reproducibility as well as absolute quantification (thus avoiding 
the need of reference genes). The authors provide an interesting 
example of dPCR quantitation of low abundance transcripts that 
can be present within EVs.
In his opinion article, Al-Nedawi discusses the Janus-faced 
implications of exosomes in cancer biology. Indeed, some 
controversies arise from the fact that exosomes can transfer 
tumor-promoting molecules (e.g., oncoproteins) and tumor sup-
pressors. The author intends to make sense of seemingly opposite 
findings such as tumor suppressor PTEN or VEGF receptor-2 
(VEGFR2) triggering the angiogenic switch to initiate angiogen-
esis. Exosomes can carry mRNAs and miRNA (miR) that can 
have various effects on tumor progression by modulating tumor 
microenvironment. An interesting cross talk implying miR-122 
is discussed. Also, the double-edge sword implications relating 
tumor-associated macrophages, VEGF, miR-150, miR-142, and 
miR-223 are detailed.
In their research article, Gong et  al. tackle the issue of 
drug resistance and metastasis. Generally, these two issues are 
addressed separately. However, recent evidence associates resist-
ance with an enhanced metastatic capacity. The authors, who 
previously described the intercellular transfer of drug resistance 
via submicron vesicles called microparticles, now propose that 
these vesicles derived from drug-resistant cells are also involved 
in the intercellular transfer of components to enhance the migra-
tion and invasion capacity of cells. As such, they might be a chan-
nel between resistance and metastasis. Using microarrays, they 
identify regulatory miRNAs. Among them, miR-503 is inversely 
associated with metastasis, as demonstrated using wound healing/
scratch migration assays and matrigel-coated transwell invasion 
assays. Their functional characterization goes beyond the direct 
transfer of vesicle components.
The review of Zocco et  al. discusses recent reports about 
the clinical utility and current limitations of exosomes and 
microvesicles for therapeutic and diagnostic applications (thera-
nostics). The authors provide a summary of recent preclinical and 
clinical studies on EV-shuttled biomarkers that may prove useful 
for screening and/or early diagnosis. They also discuss current 
technological challenges that the EV community is facing for 
the development of EV-based diagnosis approaches. The central 
issue of EV isolation protocols is detailed. Being sub-optimal, 
our current protocols produce EVs of variable yield, purity (ori-
gin), and integrity, making them poorly compatible with routine 
use for diagnostic purposes. As therapy is concerned, EVs may 
be exploited as biomimetic nanocarriers. Finally, the authors 
debate the two main limitations of these studies: the lack of 
standardized protocols for isolation of clinical grade EVs (sub)
populations and the partial understanding of the mechanisms 
involving EVs.
This research topic collates research findings that illustrate 
tightly regulated EVs feedback loops necessary within a physi-
ological context (dynamical equilibrium) and whose deregula-
tion can lead to pathological disorders. The importance of cells’ 
environment is highlighted. As nanoshuttles of biomarkers and/
or anti-tumor drugs, exosomes open new avenues for the clinical 
management of cancer. However, the lack of standardized isola-
tion protocols in this emergent field currently hampers clinical 
studies.
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